Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101 Supporting Therapeutic Potential of Anchored Immunotherapy
20 Apr 2023
Phase 1ImmunotherapyAACRClinical Result
BOSTON--(BUSINESS WIRE)--Ankyra Therapeutics, a pre-clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for cytokine drugs, announced today that it will be presenting data from a canine clinical trial of cANK-101 at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, FL.
'we are learning information about the pharmacology and immunology of cANK-101 in the dogs that will be relevant as we develop a comparable agent for humans with cancer.'
Ankyra Therapeutics has developed an anchored drug-delivery platform based on linking immunotherapy drugs to aluminum hydroxide. The linked compounds are delivered locally to the tumor, where they are retained for several weeks promoting anti-tumor activity while preventing systemic toxicity. cANK-101 is a novel agent comprised of canine interleukin-12 complexed with aluminum hydroxide using the Ankyra platform. An exploratory phase I clinical trial of cANK-101 in dogs with malignant melanoma was designed by and is being conducted at the University of Illinois College of Veterinary Medicine with Timothy Fan, DVM, PhD, as principal investigator.
“We have been delighted to work with Dr. Fan on bringing a potentially new immuno-oncology drug to dogs with malignant melanoma who have few other effective therapeutic options,” stated Howard L. Kaufman, MD, CEO of Ankyra Therapeutics. Dr. Kaufman also stated that “we are learning information about the pharmacology and immunology of cANK-101 in the dogs that will be relevant as we develop a comparable agent for humans with cancer.”
“Our experience with cANK-101 in dogs with advanced melanoma strongly suggests that the drug is well tolerated. We are seeing few side effects in treated dogs,” said Dr. Fan, a professor of veterinary clinical medicine at the University of Illinois. “We are excited about observed cyto-reductive activities and will be following the dogs to determine the clinical impact and durability of response that cANK-101 may have on a difficult-to-treat cancer in dogs.”
The poster presentation at the 2023 annual AACR meeting highlights the following prelimary data:
cANK-101 is a canine interleukin-12 linked to an aluminum hydroxide scaffold designed for direct injection into established canine tumors
An exploratory phase 1 study was designed using a standard 3+3 design with increasing doses of cANK-101 (1, 3, 10, and 20 ug/kg) given by intratumoral injection every three weeks to dogs with locally advanced or metastatic melanoma
To date, 9 dogs have been enrolled (1 cutaneous melanoma, 8 mucosal melanoma) with dose escalation on-going
To date, there have been no dose-limiting toxicities noted, with a subset of patients developing transient grade 1-2 local injection site reactions
cANK-101 pharmacokinetics and immune biomarker data suggest cANK-101 induces local interferon-gamma and results in T cell recruitment to the tumor site
One dog has achieved a strong objective response (near complete response) at the 3 ug/kg dose and clinical responses at higher doses will be reported with further follow-up
Title: Preliminary results of an exploratory phase I clinical trial of anchored canine interleukin-12 (cANK-101) in dogs with advanced oral malignant melanoma
Session Category: Immunology
Session Title: Anticancer Immunotherapeutics
Session Date and Time: Wednesday Apr 19, 2023 9:00 AM - 12:30 PM
Location: Poster Section 22
Poster Board Number: 23
Published Abstract Number: 6347
The poster will be available on the publications section of Ankyra’s website at https://ankyratx.com/#science.
About ANK-101
ANK-101 is an investigational drug composed of human interleukin-12 (IL-12) molecules with an alum-binding peptide linked to aluminum hydroxide. ANK-101 is intended for direct intratumoral injection into established tumors. A phase I clinical trial is planned to evaluate the safety and identify a recommended Phase 2 dose for ANK-101 in patients with cancer.
About Ankyra Therapeutics
Ankyra Therapeutics is a biotechnology company developing a novel approach to treating cancer, designed to expand the therapeutic window of cytokine drugs. Cytokine treatments have shown to be effective in treating cancer, but systemic dosing is limited by broad immune activation and toxicity. Using its proprietary Anchored Immunotherapy Platform, Ankyra has developed methods to localize cytokines specifically and persistently in tumor tissue, creating intense hot spots of inflammation that awaken an anti-tumor immune response. Using its platform, the company is building a pipeline of therapeutics designed to provide prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity. For more information, please visit www.ankyratx.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.